Pulse Biosciences, Inc. (PLSE) Stock Analysis & Investment Frameworks
Pulse Biosciences, Inc. (PLSE) stock analysis on Invetso. Review Pulse Biosciences, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Pulse Biosciences, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Medical - Instruments & Supplies
- Country: US
Pulse Biosciences, Inc. Key Financial Metrics
- Market Cap: $3.79B
- Revenue: $350000.00
- ROE: -77.88%
- ROIC: -45.79%
- Dividend Yield: N/A
About Pulse Biosciences, Inc.
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.